Gefitinib (NSC715055), a type of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, is an FDA‐approved drug for treating non‐small‐cell lung cancer (NSCLC). This evidence concerns the gene EGFR and non-small cell lung carcinoma.